ISRCTN10840798 https://doi.org/10.1186/ISRCTN10840798

Phase I Trial: Quotient Code QSC303299

Submission date 23/01/2026	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 06/02/2026	**Overall study status** Deferred	
Last Edited 06/02/2026	**Condition category** Other	

Plain English summary of protocol
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Principal investigator

Contact name
Dr Philip Evans

Contact details
Mere Way, Ruddington Fields, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)
Scientific, Public

Contact name
Dr Vicore Study Doctor

Contact details
Kornhamnstorg 53
Stockholm
Sweden
111 27
+46 (0)317880560
karin.eklund.vanderpol@vicorepharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1013082

Study information

Scientific Title
Phase I Trial: Quotient Code QSC303299 [the full scientific title will be published within 30 months after the end of the trial]

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 05/01/2026, London - Harrow REC (Health Research Authority, 2 Redman Place, Stratford, London, E201JQ, United Kingdom; +44 (0)2071048178; harrow.rec@hra.nhs.uk), ref: 26/LO/0005

Primary study design
Interventional

Allocation
N/A: single arm study

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose
Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
1. The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. measured using - at -

Key secondary outcome(s)

Completion date
22/05/2026

Eligibility

Key inclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed
Yes

Age group
Mixed

Lower age limit
30 Years

Upper age limit
65 Years

Sex
Male

Total final enrolment
0

Key exclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
07/03/2026

Date of final enrolment
22/05/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

Sponsor information

Organisation
Vicore Pharma (Sweden)

ROR
https://ror.org/00mkdy143

Funder(s)

Funder type

Funder Name
Vicore Pharma

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available